Unlock new possibilities and drive progress
“We are on the threshold of a new era—where cutting-edge science and AI-driven innovation unlock possibilities once thought impossible.”
— Inspired by Louis Pasteur & John von Neumann
AI/ML Innovations Inc. is a driven team of entrepreneurial technology executives, world-class scientists, AI researchers, and medical experts— all leaders in their fields—who are dedicated to redefining cardiovascular diagnostics through groundbreaking technology.
Our team brings together deep expertise in machine learning, biomedical engineering, and clinical cardiology, enabling us to develop AI-driven ECG solutions that go beyond traditional diagnostics. By harnessing advanced signal processing, predictive analytics, and real-time data interpretation, we are making heart health more accessible, accurate, and proactive.
With our innovative approaches, we aim to bridge the gap between raw biometric data and actionable clinical insights, empowering healhcare professionals with deeper diagnostic precision while giving individuals greater control over their heart health.
Our technology is designed to integrate seamlessly into existing ecosystem of medical systems, wearable devices, and digital health platforms, ensuring that cutting-edge cardiovascular care is available anytime, anywhere.
As we continue to push the boundaries of AI in healthcare, our goal remains clear: to revolutionize the way heart disease is detected, monitored, and prevented—ultimately saving lives on a global scale.
Meet the Team
Paul Duffy
Executive Chairman and CEO
Paul Duffy brings over 30 years of dynamic leadership and a proven track record in the commercialization of digital technologies. Before joining AI/ML Innovations Inc, Paul was President and Chairman of NexTech3D.AI (CSE: NTAR) and Co-founder and CEO of ARHT Media Inc. (TSXV: ART), where he demonstrated exceptional leadership in inventing, patenting, and commercializing numerous technologies using AI, AR and Holograms. Mr. Duffy's leadership will drive the company’s mission to harness the revolutionary potential of AI and ML in the burgeoning digital health and wellbeing sector and other high growth domains.
Peter Kendall
Director and CCO
With a distinguished career spanning senior leadership roles at TELUS Health, Medisys, Lifemark, and 3M, Mr. Kendall brings extensive expertise in revenue generation, strategic planning, and team leadership. An accomplished leader in healthcare and technology, Mr. Kendall has consistently driven organizational growth and innovation. His proven ability to scale businesses, cultivate strategic alliances, and optimize operations has made him a transformative force across Canada, the US, and Europe.
Dr. Alan Rabinowitz
Chief Medical Officer
Dr. Alan Rabinowitz was formerly Director of the Coronary Care Unit at St Paul’s Hospital and is currently a cardiologist and Clinical Associate Professor in the Division of Cardiology at St Paul’s Hospital. Alan has held numerous advisory roles to both public and private healthcare entities globally and has also been at the forefront of various entrepreneurial initiatives with a specific focus on disruptive innovation and data innovation in healthcare and the life sciences. Alan received his medical degree from the University of Cape Town, South Africa, completed his internal medicine and cardiology training at the University of Toronto and undertook subsequent training in interventional cardiology at St. Paul’s Hospital, University of British Columbia (“UBC”) in Vancouver, Canada.
Esmat Naikyar
Chief Product Officer
Esmat Naikyar brings a wealth of knowledge and enthusiasm to his role as Interim Chief Product Officer. His background showcases a strong foundation in leading start-ups that pioneer a future where AI and big data converge to transform healthcare through the design and implementation of systems that employ AI for automated decision making. Esmat is at the forefront of guiding AIML's subsidiary, Health Gauge Inc., in the development of advanced Neural Networks, contributing to the ongoing evolution of Artificial Intelligence and Machine Learning applications in healthcare.
Terence Lee
Chief Financial Officer
Terence Lee is a Chartered Professional Accountant (“CPA”) with 11 years of progressive finance experience and in-depth knowledge reporting under International Financial Reporting Standards. Terence has worked in various financial reporting and financial planning roles, for both private and public companies, within various sectors including: Life Sciences, Health Care, Technology, and Mining. Terence holds a Bachelor of Business Administration (finance) from Simon Fraser University and a Diploma of Accounting from UBC. He obtained his CPA designation while articling with BDO Canada LLP where he specialized in financial audits of public companies. Terence is con-currently a partner at Imperium Consulting LLP, a Vancouver-based accounting and advisory firm.
Kendra Low
Corporate Secretary
With more than 20 years’ experience working in corporate and sustainability governance, Kendra is an experienced and respected corporate secretary, governance professional and business strategist. She has advised boards and managed the governance function of publicly traded, private, and not-for-profit organizations through all stages of growth and in a wide variety of industries. She is the CEO of Vancouver Corporate Solutions Inc. and Kalamandra Consulting Inc. Kendra holds a Master of Business Administration (MBA) and a Bachelor of Kinesiology from the University of British Columbia.
Dr. Paul Dorian
MD, MSc, FRCPC, FACC — Professor of Medicine, University of Toronto; Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital
Dr. Paul Dorian is an internationally respected clinician–scientist with more than 35 years of experience in arrhythmia management, sudden‑cardiac‑death prevention, and cardiovascular pharmacology. A prolific investigator, he has authored 400+ peer‑reviewed publications and led landmark trials on atrial‑fibrillation therapy and cardiac arrest outcomes. Dr. Dorian has chaired guideline committees for the Canadian Cardiovascular Society (CCS) and served as Associate Editor of Circulation. At St. Michael’s Hospital he directs the Cardiac Electrophysiology Fellowship, mentoring the next generation of EP specialists.
Dr. Alan Rabinowitz
MBChB, FRCPC, FACC — Chief Medical Officer, AIML; Cardiologist and formerly Director of the Coronary Care Unit, St. Paul's Hospital Heart Centre/ Center for Heart Lung Innovation; Clinical Associate Professor, Division of Cardiology, University of British Columbia
Dr. Alan Rabinowitz received his medical degree from the University of Cape Town, South Africa, completed his internal medicine and cardiology training at the University of Toronto and undertook subsequent training in interventional cardiology at St Paul’s Hospital, University of British Columbia. He was formerly Director of the Coronary Care Unit at St Paul’s Hospital and is currently a cardiologist and Clinical Associate Professor in the Division of Cardiology at St Paul’s Hospital. Alan has held numerous advisory roles to both public and private healthcare entities globally. These include the www.RCCbc.ca ,which coordinates healthcare on behalf of the citizens of rural British Columbians with strong focus on health system transformation for Indigenous and other rural populations. Stemming from his term as President of the Medical Staff Association at Providence Healthcare BC he has had various advisory positions on the New St Paul’s Hospital and Health Campus Redevelopment Project. He has also been at the forefront of numerous entrepreneurial initiatives with a specific focus on disruptive innovation and data innovation in healthcare and the life sciences. Most recently these have centered on translational and phenomics medicine within a framework of social accountability and value- based medicine. Public-private partnerships are an integral part of these initiatives.
Dr. Brett Heilbron
MBChB, FRCPC, FACC — Medical Director, Electrodiagnostics Program; Clinical Associate Professor, Division of Cardiology, University of British Columbia; St. Paul’s Hospital Heart Centre, Vancouver, BC
Dr. Brett Heilbron completed his undergraduate degree at the University of Cape Town (South Africa), and then practiced as a rural family physician in Newfoundland and Manitoba for 4 years. He completed Internal Medicine and Cardiology training at the University of British Columbia in 1995. He has Level 3 Certification in Cardiac Computed Tomography and is a Diplomate of the Certification Board in Cardiac Computed Tomography and a Fellow of the Society of Cardiovascular Computed Tomography. He has been based at St. Paul’s Hospital since 1997, where he has a clinical practice and works in the Cardiac Catheterization Laboratory. He is Medical Director of the Electrodiagnostics program at St. Paul’s Hospital and Mount St. Joseph’s Hospital, and a Clinical Associate Professor at the University of British Columbia. He is the Cardiology Consultant for Lifelabs British Columbia.
Marc W. Deyell
MD, MSc FHRS FCCS — Clinical Professor, University of British Columbia; Director, Heart Rhythm Services, St. Paul’s Hospital
Dr. Marc Deyell is a leading electrophysiologist and clinical researcher whose work spans ventricular‑tachycardia ablation, inherited arrhythmic syndromes, and signal‑processing innovations. As Director of EP at UBC, he supervises a multi‑disciplinary team conducting first‑in‑human trials of AI‑driven ECG analytics—research that underpins MaxYield’s validation datasets. Dr. Deyell has received the Canadian Institutes of Health Research (CIHR) New Investigator Award and routinely advises Health Canada on novel device approvals in electrophysiology.
Dr. Kim Connelly
MBBS, PhD, FRACP, FRCPC — Professor of Medicine and Physiology, University of Toronto; Cardiologist and Scientist, St. Michael’s Hospital
Dr. Kim Connelly is a clinician‑scientist recognized for translational research in diabetic cardiomyopathy, advanced cardiac imaging, and regenerative therapies. He directs the Cardio‑Metabolic Research Program at St. Michael’s, where his lab integrates machine‑learning biomarkers with MRI and echo phenotyping. Dr. Connelly has secured >$15 million in competitive funding and has been a key investigator on cell‑based therapy trials for heart failure. His expertise in imaging‑defined endpoints complements MaxYield’s roadmap toward AI‑image data fusion.
Peter Kendall
Chairman, Medical Advisory Board
Peter Kendall, President and Chief Commercialization Officer, will serve as Chair of the Medical Advisory Board, ensuring a strong bridge between clinical insight and AIML’s commercialization strategy. With more than two decades of experience leading go-to-market programs for breakthrough health technologies, Peter is uniquely positioned to translate scientific and clinical guidance into scalable solutions. Under his leadership, the Board’s recommendations will be integrated into AIML’s core operations—ensuring that clinical guidance translates directly into product development, regulatory strategy, and commercial execution.
Paul Duffy
Executive Chairman and CEO
Paul Duffy brings over 30 years of dynamic leadership and a proven track record in the commercialization of digital technologies. Before joining AI/ML Innovations Inc, Paul was President and Chairman of NexTech3D.AI (CSE: NTAR) and Co-founder and CEO of ARHT Media Inc. (TSXV: ART), where he demonstrated exceptional leadership in inventing, patenting, and commercializing numerous technologies using AI, AR and Holograms. Mr. Duffy's leadership will drive the company’s mission to harness the revolutionary potential of AI and ML in the burgeoning digital health and wellbeing sector and other high growth domains.
Dr. Drew Dundas
Independent Director
Dr. Dundas brings over two decades of leadership in technology and research, currently serving as Chief Technology Officer at Earlens Corporation, where he leads research and development efforts across various teams, including research, audiology, marketing, and clinical. Prior to Earlens, Dr. Dundas served as President and CTO of Soundhawk Corporation and Director of Audiology at UCSF Medical Center. His background also includes research at Starkey Hearing Technologies, where he contributed to the development of groundbreaking audiological technologies. Dr. Dundas holds a PhD in Audiology & Biomedical Engineering from Vanderbilt University, a Master of Arts from The University of Akron in Audiology, and a BSc from McMaster University. In addition, Dr. Dundas is a fellow of the American Academy of Audiology.
Jared Adelstein
Independent Director
Mr. Adelstein brings almost a decade of experience in investment banking and capital markets, having worked with several boutique firms in Toronto. His career has been dedicated to advising innovative, high-growth early-stage companies, both in capital markets and operational capacities. He possesses a robust expertise in forecasting and budgeting, operational planning, and capital raising.
Peter Kendall
Director and CCO
With a distinguished career spanning senior leadership roles at TELUS Health, Medisys, Lifemark, and 3M, Mr. Kendall brings extensive expertise in revenue generation, strategic planning, and team leadership. An accomplished leader in healthcare and technology, Mr. Kendall has consistently driven organizational growth and innovation. His proven ability to scale businesses, cultivate strategic alliances, and optimize operations has made him a transformative force across Canada, the US, and Europe.
Michael Diamond
Independent Director
Mr. Diamond is a Principal of Upstream Strategy Group, a respected public affairs and strategic communications firm. He also serves as the President of the Ontario Progressive Conservative Party and is widely regarded as one of Canada’s most influential voices in political strategy, regulatory affairs, and stakeholder engagement. In addition to his deep expertise in public policy, Mr. Diamond brings a proven ability to build partnerships, drive business development, and align innovation with government priorities. His strategic lens and real-world experience at the intersection of politics, business, and innovation will directly support AIML’s efforts to scale its AI-powered health technologies across regulated markets.